sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant
The receptor for advanced glycation end products (RAGE) and its gene (AGER) have been related to lung injury and inflammatory diseases, including chronic obstructive pulmonary disease (COPD). We aimed to evaluate the association of rs2071288, rs3134940, rs184003, and rs2070600 AGER single-nucleotide...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024047066 |
| _version_ | 1797242968486182912 |
|---|---|
| author | Ingrid Fricke-Galindo Salvador García-Carmona Jesús Alanis-Ponce Gloria Pérez-Rubio Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson Robles-Hernández Rafael de Jesús Hernández-Zenteno Daniela Valencia-Pérez Rea Brandon Bautista-Becerril María Elena Ramírez-Díaz Filiberto Cruz-Vicente María de Lourdes Martínez-Gómez Raúl Sansores Ramcés Falfán-Valencia |
| author_facet | Ingrid Fricke-Galindo Salvador García-Carmona Jesús Alanis-Ponce Gloria Pérez-Rubio Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson Robles-Hernández Rafael de Jesús Hernández-Zenteno Daniela Valencia-Pérez Rea Brandon Bautista-Becerril María Elena Ramírez-Díaz Filiberto Cruz-Vicente María de Lourdes Martínez-Gómez Raúl Sansores Ramcés Falfán-Valencia |
| author_sort | Ingrid Fricke-Galindo |
| collection | DOAJ |
| description | The receptor for advanced glycation end products (RAGE) and its gene (AGER) have been related to lung injury and inflammatory diseases, including chronic obstructive pulmonary disease (COPD). We aimed to evaluate the association of rs2071288, rs3134940, rs184003, and rs2070600 AGER single-nucleotide variants and the soluble-RAGE plasma and sputum levels with COPD secondary to biomass-burning smoke (BBS) and tobacco smoking. Four groups, including 2189 subjects, were analyzed: COPD secondary to BBS exposure (COPD-BBS, n = 342), BBS-exposed subjects without COPD (BBES, n = 774), tobacco smoking-induced COPD (COPD-TS, n = 434), and smokers without COPD (SWOC, n = 639). Allelic discrimination assays determined the AGER variants. The sRAGE was quantified in plasma (n = 240) and induced-sputum (n = 72) samples from a subgroup of patients using the ELISA technique. In addition, a meta-analysis was performed for the association of rs2070600 with COPD susceptibility. None of the studied genetic variants were found to be associated with COPD-BBS or COPD-TS. A marginal association was observed for the rs3134940 with COPD-BBS (p = 0.066). The results from the meta-analysis, including six case-control studies (n = 4149 subjects), showed a lack of association of rs2070600 with COPD susceptibility (p = 0.681), probably due to interethnic differences. The sRAGE plasma levels were lower in COPD-BBS compared to BBS and in COPD-TS compared to SWOC. The sRAGE levels were also lower in sputum samples from COPD-BBS than BBES. Subjects with rs3134940-TC genotypes exhibit lower sRAGE plasma levels than TT subjects, mainly from the COPD-BBS and SWOC groups. The AGER variants were not associated with COPD-BBS nor COPD-TS, but the sRAGE plasma and sputum levels are related to both COPD-BBS and COPD-TS and are influenced by the rs3134940 variant. |
| first_indexed | 2024-04-24T18:47:39Z |
| format | Article |
| id | doaj.art-a4086f9455fd40c5993d5a35d5a14011 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-24T18:47:39Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-a4086f9455fd40c5993d5a35d5a140112024-03-27T04:52:41ZengElsevierHeliyon2405-84402024-04-01107e28675sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variantIngrid Fricke-Galindo0Salvador García-Carmona1Jesús Alanis-Ponce2Gloria Pérez-Rubio3Alejandra Ramírez-Venegas4Francisco Montiel-Lopez5Robinson Robles-Hernández6Rafael de Jesús Hernández-Zenteno7Daniela Valencia-Pérez Rea8Brandon Bautista-Becerril9María Elena Ramírez-Díaz10Filiberto Cruz-Vicente11María de Lourdes Martínez-Gómez12Raúl Sansores13Ramcés Falfán-Valencia14HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoTobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, MexicoTobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, MexicoTobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, MexicoTobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, MexicoCoordinación de Vigilancia Epidemiológica, Jurisdicción 06 Sierra, Tlacolula de Matamoros Oaxaca, Servicios de Salud de Oaxaca, Oaxaca, 70400, MexicoInternal Medicine Department, Hospital Civil Aurelio Valdivieso, Servicios de Salud de Oaxaca, Oaxaca, 68050, MexicoHospital Regional de Alta Especialidad de Oaxaca, Oaxaca, 71256, MexicoClínica de Enfermedades Respiratorias, Fundación Médica Sur, Mexico City, 14080, MexicoHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, Mexico; Corresponding author. HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Calzada de Tlalpan 4502, Sección XVI, Mexico City, 14080, Mexico.The receptor for advanced glycation end products (RAGE) and its gene (AGER) have been related to lung injury and inflammatory diseases, including chronic obstructive pulmonary disease (COPD). We aimed to evaluate the association of rs2071288, rs3134940, rs184003, and rs2070600 AGER single-nucleotide variants and the soluble-RAGE plasma and sputum levels with COPD secondary to biomass-burning smoke (BBS) and tobacco smoking. Four groups, including 2189 subjects, were analyzed: COPD secondary to BBS exposure (COPD-BBS, n = 342), BBS-exposed subjects without COPD (BBES, n = 774), tobacco smoking-induced COPD (COPD-TS, n = 434), and smokers without COPD (SWOC, n = 639). Allelic discrimination assays determined the AGER variants. The sRAGE was quantified in plasma (n = 240) and induced-sputum (n = 72) samples from a subgroup of patients using the ELISA technique. In addition, a meta-analysis was performed for the association of rs2070600 with COPD susceptibility. None of the studied genetic variants were found to be associated with COPD-BBS or COPD-TS. A marginal association was observed for the rs3134940 with COPD-BBS (p = 0.066). The results from the meta-analysis, including six case-control studies (n = 4149 subjects), showed a lack of association of rs2070600 with COPD susceptibility (p = 0.681), probably due to interethnic differences. The sRAGE plasma levels were lower in COPD-BBS compared to BBS and in COPD-TS compared to SWOC. The sRAGE levels were also lower in sputum samples from COPD-BBS than BBES. Subjects with rs3134940-TC genotypes exhibit lower sRAGE plasma levels than TT subjects, mainly from the COPD-BBS and SWOC groups. The AGER variants were not associated with COPD-BBS nor COPD-TS, but the sRAGE plasma and sputum levels are related to both COPD-BBS and COPD-TS and are influenced by the rs3134940 variant.http://www.sciencedirect.com/science/article/pii/S2405844024047066COPDAGERsRAGEPolymorphismReceptor for advanced glycation end productsBiomass-burning smoke |
| spellingShingle | Ingrid Fricke-Galindo Salvador García-Carmona Jesús Alanis-Ponce Gloria Pérez-Rubio Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson Robles-Hernández Rafael de Jesús Hernández-Zenteno Daniela Valencia-Pérez Rea Brandon Bautista-Becerril María Elena Ramírez-Díaz Filiberto Cruz-Vicente María de Lourdes Martínez-Gómez Raúl Sansores Ramcés Falfán-Valencia sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant Heliyon COPD AGER sRAGE Polymorphism Receptor for advanced glycation end products Biomass-burning smoke |
| title | sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant |
| title_full | sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant |
| title_fullStr | sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant |
| title_full_unstemmed | sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant |
| title_short | sRAGE levels are decreased in plasma and sputum of COPD secondary to biomass-burning smoke and tobacco smoking: Differences according to the rs3134940 AGER variant |
| title_sort | srage levels are decreased in plasma and sputum of copd secondary to biomass burning smoke and tobacco smoking differences according to the rs3134940 ager variant |
| topic | COPD AGER sRAGE Polymorphism Receptor for advanced glycation end products Biomass-burning smoke |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024047066 |
| work_keys_str_mv | AT ingridfrickegalindo sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT salvadorgarciacarmona sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT jesusalanisponce sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT gloriaperezrubio sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT alejandraramirezvenegas sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT franciscomontiellopez sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT robinsonrobleshernandez sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT rafaeldejesushernandezzenteno sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT danielavalenciaperezrea sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT brandonbautistabecerril sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT mariaelenaramirezdiaz sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT filibertocruzvicente sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT mariadelourdesmartinezgomez sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT raulsansores sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant AT ramcesfalfanvalencia sragelevelsaredecreasedinplasmaandsputumofcopdsecondarytobiomassburningsmokeandtobaccosmokingdifferencesaccordingtothers3134940agervariant |